Logo image of CSPR

Casper Sleep Inc (CSPR) Stock Fundamental Analysis

NYSE:CSPR - New York Stock Exchange, Inc. - Common Stock

6.78  +0.48 (+7.62%)

Premarket: 6.71 -0.07 (-1.03%)

Fundamental Rating

1

CSPR gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 63 industry peers in the Household Durables industry. CSPR has a bad profitability rating. Also its financial health evaluation is rather negative. CSPR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CSPR has reported negative net income.
CSPR Yearly Net Income VS EBIT VS OCF VS FCFCSPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 -20M -40M -60M -80M

1.2 Ratios

Industry RankSector Rank
ROA -43.28%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CSPR Yearly ROA, ROE, ROICCSPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 -200 -400 -600

1.3 Margins

Industry RankSector Rank
OM -11.31%
PM (TTM) -16.24%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CSPR Yearly Profit, Operating, Gross MarginsCSPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 0 20 -20 40

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, CSPR has more shares outstanding
The debt/assets ratio for CSPR is higher compared to a year ago.
CSPR Yearly Shares OutstandingCSPR Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 10M 20M 30M 40M
CSPR Yearly Total Debt VS Total AssetsCSPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -1.27, we must say that CSPR is in the distress zone and has some risk of bankruptcy.
CSPR has a Debt/Equity ratio of -1.18. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity -1.18
Debt/FCF N/A
Altman-Z -1.27
ROIC/WACCN/A
WACCN/A
CSPR Yearly LT Debt VS Equity VS FCFCSPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 0.87 indicates that CSPR may have some problems paying its short term obligations.
CSPR has a Quick Ratio of 0.87. This is a bad value and indicates that CSPR is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.87
Quick Ratio 0.46
CSPR Yearly Current Assets VS Current LiabilitesCSPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 50M 100M 150M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 59.42% over the past year.
CSPR shows a strong growth in Revenue. In the last year, the Revenue has grown by 23.79%.
CSPR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 25.59% yearly.
EPS 1Y (TTM)59.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-56.41%
Revenue 1Y (TTM)23.79%
Revenue growth 3Y25.59%
Revenue growth 5YN/A
Sales Q2Q%26.75%

3.2 Future

The Earnings Per Share is expected to grow by 6.82% on average over the next years.
CSPR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.02% yearly.
EPS Next Y28.13%
EPS Next 2Y21.54%
EPS Next 3Y17.23%
EPS Next 5Y6.82%
Revenue Next Year24.47%
Revenue Next 2Y19.52%
Revenue Next 3Y17.78%
Revenue Next 5Y16.02%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
CSPR Yearly Revenue VS EstimatesCSPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B
CSPR Yearly EPS VS EstimatesCSPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CSPR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CSPR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CSPR Price Earnings VS Forward Price EarningsCSPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -6.22
CSPR Per share dataCSPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A more expensive valuation may be justified as CSPR's earnings are expected to grow with 17.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.54%
EPS Next 3Y17.23%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CSPR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Casper Sleep Inc

NYSE:CSPR (1/24/2022, 8:33:37 PM)

Premarket: 6.71 -0.07 (-1.03%)

6.78

+0.48 (+7.62%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Durables & Apparel
GICS IndustryHousehold Durables
Earnings (Last)N/A N/A
Earnings (Next)02-28 2022-02-28/bmo
Inst Owners0.04%
Inst Owner Change0%
Ins Owners13.73%
Ins Owner Change0%
Market Cap282.18M
Analysts72.86
Price Target7.52 (10.91%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.48
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA -6.22
EPS(TTM)-1.83
EYN/A
EPS(NY)-1.24
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS14.09
BVpS-1.03
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -43.28%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -11.31%
PM (TTM) -16.24%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover2.66
Health
Industry RankSector Rank
Debt/Equity -1.18
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.87
Quick Ratio 0.46
Altman-Z -1.27
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-56.41%
EPS Next Y28.13%
EPS Next 2Y21.54%
EPS Next 3Y17.23%
EPS Next 5Y6.82%
Revenue 1Y (TTM)23.79%
Revenue growth 3Y25.59%
Revenue growth 5YN/A
Sales Q2Q%26.75%
Revenue Next Year24.47%
Revenue Next 2Y19.52%
Revenue Next 3Y17.78%
Revenue Next 5Y16.02%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A